NLS Pharmaceutics Ltd. — Investor Relations & Filings
Filings indexed
360
across all filing types
Latest filing
2022-12-22
Regulatory Filings
Country
US
United States of America
Listing
US
NLSP
NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for patients with rare and complex central nervous system (CNS) disorders. The company's primary focus areas include sleep disorders, neurodegenerative diseases, and attention-deficit/hyperactivity disorder (ADHD). Its lead product candidates are Quilience, a proprietary extended-release formulation of mazindol for the treatment of narcolepsy, and Nolazol for ADHD. NLS Pharmaceutics is also advancing its pipeline with additional assets, such as the AEX-6xx series, to address other CNS-related conditions.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| REPORT OF FOREIGN PRIVATE ISSUER | 2022-12-22 | English | |
| Regulatory Filings 2022 | 2022-12-21 | English | |
| REPORT OF FOREIGN PRIVATE ISSUER | 2022-12-20 | English | |
| AMENDMENT NO. 1 TO FORM 6-K | 2022-12-16 | English | |
| THE SCHEDULE 13G | 2022-12-16 | English | |
| Regulatory Filings 2022 | 2022-12-16 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2022
15 filings
| |||||
| 13193391 | REPORT OF FOREIGN PRIVATE ISSUER | 2022-12-22 | English | ||
| 13193392 | Regulatory Filings 2022 | 2022-12-21 | English | ||
| 13193393 | REPORT OF FOREIGN PRIVATE ISSUER | 2022-12-20 | English | ||
| 13193394 | AMENDMENT NO. 1 TO FORM 6-K | 2022-12-16 | English | ||
| 13193395 | THE SCHEDULE 13G | 2022-12-16 | English | ||
| 13193396 | Regulatory Filings 2022 | 2022-12-16 | English | ||
| 13193397 | CURRENT REPORT | 2022-12-14 | English | ||
| 13193400 | REPORT OF FOREIGN PRIVATE ISSUER | 2022-12-14 | English | ||
| 13193398 | Regulatory Filings 2022 | 2022-12-13 | English | ||
| 13193399 | Regulatory Filings 2022 | 2022-12-13 | English | ||
| 13193401 | REPORT OF FOREIGN PRIVATE ISSUER | 2022-12-08 | English | ||
| 13193402 | REPORT OF FOREIGN PRIVATE ISSUER | 2022-12-07 | English | ||
| 13193403 | REGISTRATION STATEMENT | 2022-12-06 | English | ||
| 13193404 | REPORT OF FOREIGN PRIVATE ISSUER | 2022-12-01 | English | ||
| 13193405 | REPORT OF FOREIGN PRIVATE ISSUER | 2022-11-23 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
NLS Pharmaceutics Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35193/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35193 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35193 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35193 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35193}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for NLS Pharmaceutics Ltd. (id: 35193)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.